US FDA lifts clinical hold on Intellia's nerve disease trail

Core Viewpoint - Intellia Therapeutics has received approval from the U.S. Food and Drug Administration to lift a clinical hold on one of its late-stage gene therapy trials, enabling the company to resume testing its experimental treatment [1] Group 1 - The FDA's decision allows Intellia to continue its clinical trial, which is crucial for the development of its gene therapy [1] - The lifting of the clinical hold is a significant milestone for Intellia, potentially impacting its future growth and market position [1]